Published in Bioorg Med Chem Lett on September 29, 2007
3D-QSAR study of Chk1 kinase inhibitors based on docking. J Mol Model (2012) 0.81
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res (2008) 9.65
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med (2013) 8.89
Distinctive chromatin in human sperm packages genes for embryo development. Nature (2009) 6.18
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res (2007) 5.75
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov (2009) 4.12
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol (2010) 3.76
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res (2007) 3.24
Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos (2008) 2.45
The draft genome of watermelon (Citrullus lanatus) and resequencing of 20 diverse accessions. Nat Genet (2012) 2.33
Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry (2004) 2.23
Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem (2003) 2.18
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther (2005) 2.15
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res (2008) 2.10
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem (2007) 2.09
Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem (2004) 2.05
Genes for embryo development are packaged in blocks of multivalent chromatin in zebrafish sperm. Genome Res (2011) 1.94
Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol Cancer Ther (2003) 1.90
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem (2008) 1.85
A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res (2006) 1.67
Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem (2006) 1.64
Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem (2002) 1.55
Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer (2006) 1.53
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol (2010) 1.47
Testosterone is associated with erectile dysfunction: a cross-sectional study in Chinese men. PLoS One (2012) 1.46
Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther (2010) 1.41
Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin Cancer Res (2011) 1.41
Induction of interleukin 2 expression in the liver for the treatment of H22 hepatoma in mice. Dig Liver Dis (2012) 1.41
Development of a high-throughput fluorescence polarization assay for Bcl-x(L). Anal Biochem (2002) 1.38
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res (2009) 1.36
The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther (2011) 1.36
Survivin enhances Aurora-B kinase activity and localizes Aurora-B in human cells. J Biol Chem (2002) 1.35
Low serum osteocalcin level is a potential marker for metabolic syndrome: results from a Chinese male population survey. Metabolism (2011) 1.34
ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther (2008) 1.34
A consensus linkage map for molecular markers and quantitative trait loci associated with economically important traits in melon (Cucumis melo L.). BMC Plant Biol (2011) 1.33
Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem (2006) 1.33
A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene (2005) 1.32
A high resolution genetic map anchoring scaffolds of the sequenced watermelon genome. PLoS One (2012) 1.32
Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther (2006) 1.30
Characterization of transcriptome dynamics during watermelon fruit development: sequencing, assembly, annotation and gene expression profiles. BMC Genomics (2011) 1.28
Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol Cancer Res (2008) 1.27
Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol (2014) 1.23
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity. J Med Chem (2015) 1.22
Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series. Biochemistry (2003) 1.19
Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug Metab Dispos (2006) 1.15
Normalization strategies for metabonomic analysis of urine samples. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.14
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res (2008) 1.12
Drug metabolite profiling and identification by high-resolution mass spectrometry. J Biol Chem (2011) 1.11
Discovery of a novel small molecule binding site of human survivin. Bioorg Med Chem Lett (2007) 1.11
Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain (2011) 1.11
Uterine artery myosin phosphatase isoform switching and increased sensitivity to SNP in a rat L-NAME model of hypertension of pregnancy. Am J Physiol Cell Physiol (2007) 1.08
A genome-wide association and gene-environment interaction study for serum triglycerides levels in a healthy Chinese male population. Hum Mol Genet (2011) 1.06
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension. J Med Chem (2007) 1.06
Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models. Clin Cancer Res (2005) 1.03
The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J Immunol (2009) 1.03
Genome-wide association study identifies novel loci associated with serum level of vitamin B12 in Chinese men. Hum Mol Genet (2012) 1.02
Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg Med Chem Lett (2010) 1.02
Aberrant expression of long noncoding RNAs in early diabetic retinopathy. Invest Ophthalmol Vis Sci (2014) 0.99
Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors. Bioorg Med Chem (2006) 0.99
An integrated genetic map based on four mapping populations and quantitative trait loci associated with economically important traits in watermelon (Citrullus lanatus). BMC Plant Biol (2014) 0.99
Genome-wide association study for serum complement C3 and C4 levels in healthy Chinese subjects. PLoS Genet (2012) 0.97
Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey. Urology (2011) 0.96
More protection for China's wetlands. Nature (2011) 0.95
Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression. Neoplasia (2008) 0.95
Determining Dosimetric Properties and Lowest Detectable Dose of Fingernail Clippings from their Electron Paramagnetic Resonance Signal. Health Phys (2015) 0.95
A unified, probabilistic framework for structure- and ligand-based virtual screening. J Med Chem (2011) 0.95
Epigallocatechin-gallate (EGCG) regulates autophagy in human retinal pigment epithelial cells: a potential role for reducing UVB light-induced retinal damage. Biochem Biophys Res Commun (2013) 0.94
Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency. Bioorg Med Chem Lett (2003) 0.93
ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev (2004) 0.93
Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition. Biochemistry (2004) 0.93
A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analyses. J Mass Spectrom (2003) 0.92
Serum uric acid and non-alcoholic fatty liver disease in non-diabetic Chinese men. PLoS One (2013) 0.92
Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. J Med Chem (2007) 0.91
Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics. Int J Cancer (2005) 0.91
Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo. Neoplasia (2005) 0.91
Chk1 inhibitors for novel cancer treatment. Anticancer Agents Med Chem (2006) 0.89
Pyridone-containing farnesyltransferase inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett (2003) 0.88
Detection and structural characterization of glutathione-trapped reactive metabolites using liquid chromatography-high-resolution mass spectrometry and mass defect filtering. Anal Chem (2007) 0.88